| Title | Nebivolol in obese and non-obese hypertensive patients. |
| Author(s) | Manrique C, Whaley-Connell A, Sowers JR |
| Institution | Department of Internal Medicine, University of Missouri School of Medicine, Columbia, USA. |
| Source | J Clin Hypertens (Greenwich) 2009 Jun; 11(6):309-15. |
| MeSH | Adult
Aged
Antihypertensive Agents
Benzopyrans
Blood Pressure
Carbohydrate Metabolism
Dose-Response Relationship, Drug
Double-Blind Method
Ethanolamines
Female
Humans
Hypertension
Lipid Metabolism
Male
Middle Aged
Obesity
Randomized Controlled Trials as Topic
Treatment Outcome
|
| Abstract | Use of beta-blockers in hypertensive obese patients remains controversial because of concerns about potential influences on weight, lipids, and glucose metabolism. The authors examined a pooled analysis of 3 multicenter randomized placebo-controlled trials. Patients were randomized to placebo or an increasing dose of nebivolol for 12 weeks. Primary outcome was the mean baseline to end point change in trough mean sitting diastolic blood pressure (SiDBP). Secondary outcomes were baseline to end point changes in trough sitting systolic blood pressure (SiSBP); trough standing and peak supine diastolic blood pressure and systolic blood pressure. Nebivolol reduced SiDBP significantly compared with placebo at all doses > or =2.5 mg in obese and non-obese patients. Reductions in SiSBP with nebivolol were higher than controls at all studied doses > or =5 mg in non-obese and > or =2.5 mg in obese patients. These findings and nebivolol's neutral effects on lipid and carbohydrate metabolism suggest that it is one option for blood pressure control in the moderately obese population. |
| Language | eng |
| Pub Type(s) | Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
|
| PubMed ID | 19527321 |
